Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma
Article first published online: 30 SEP 2010
Copyright © 2010 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 102, Issue 7, pages 796–801, 1 December 2010
How to Cite
Qu, L.-S., Jin, F., Huang, X.-W. and Shen, X.-Z. (2010), Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J. Surg. Oncol., 102: 796–801. doi: 10.1002/jso.21741
- Issue published online: 21 NOV 2010
- Article first published online: 30 SEP 2010
- Manuscript Accepted: 11 AUG 2010
- Manuscript Received: 10 JUN 2010
- National Basic Research Program of China. Grant Number: 2007CB936000
- Major National Science and Technology Projects. Grant Numbers: 2009ZX10004-301, 2008ZX10002-017
- Shanghai Science and Technology Commission. Grant Numbers: 10410709400, 10411950100
- Shanghai Talent Development Foundation. Grant Number: 2009-035
- National Nature Science Foundation of China. Grant Numbers: 30772505, 30872503
- hepatocellular carcinoma;
- hepatitis B virus;
A retrospective cohort study was conducted to investigate the effect of interferon-α (IFN-α) therapy after curative resection on survival and recurrence in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
Of 568 HBV-related HCC patients who underwent curative resection, 101 patients received postoperative IFN-α therapy (5 million units three times every week for 18 months). Clinicopathological factors were compared between patients with postoperative IFN-α therapy or not. Risk factors for survival, early, and late recurrence (2 years as cut-off) were studied.
The median follow-up time was 53.3 months. There was no significant difference in clinicopathological factors between the two groups. Patients with postoperative IFN-α therapy had higher overall survival rates (hazards ratio (HR): 0.612, 95% confidence interval (CI): 0.422–0.889, P = 0.010). No significant difference in disease-free survival rates was detected between the two groups (HR: 0.786, 95% CI: 0.597–1.035, P = 0.086). Multivariate analysis revealed that postoperative IFN-α therapy was an independent factor for overall survival (HR: 0.611, 95% CI: 0.421–0.887, P = 0.010) and significantly reduced early recurrence (HR: 0.562, 95% CI: 0.375–0.840, P = 0.005).
IFN-α therapy after curative resection prevented early recurrence and improved overall survival of patients with HBV-related HCC. J. Surg. Oncol. 2010;102:796–801. © 2010 Wiley-Liss, Inc.